Brophy Wealth Management LLC Acquires Shares of 7,323 Zoetis Inc. (NYSE:ZTS)

Brophy Wealth Management LLC bought a new position in Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 7,323 shares of the company’s stock, valued at approximately $1,431,000.

A number of other large investors have also modified their holdings of ZTS. Darwin Wealth Management LLC acquired a new position in Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the third quarter worth $33,000. Dunhill Financial LLC boosted its stake in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Quarry LP grew its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.9 %

NYSE ZTS opened at $178.12 on Tuesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a 50-day simple moving average of $181.72 and a 200-day simple moving average of $181.12. The firm has a market capitalization of $80.36 billion, a PE ratio of 33.48, a price-to-earnings-growth ratio of 2.88 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.36 earnings per share. On average, equities analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st were paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date of this dividend was Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average target price of $219.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.